Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | JAK2 V617F JAK2 L983F |
Therapy | Ruxolitinib |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
JAK2 V617F JAK2 L983F | Advanced Solid Tumor | resistant | Ruxolitinib | Preclinical | Actionable | In a preclinical study, transformed cells expressing JAK2 V617F and L983F demonstrated resistance to Jakafi (Ruxolitinib) treatment in cell culture and in a syngeneic mouse model (PMID: 26419724). | 26419724 |
PubMed Id | Reference Title | Details |
---|---|---|
(26419724) | Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance. | Full reference... |